Published in Neoplasia on April 01, 2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol (2014) 2.18
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov (2015) 1.06
miR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells. PLoS One (2015) 0.96
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. Cancer Discov (2016) 0.82
Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop. Oncotarget (2016) 0.81
BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer. Cancer Sci (2015) 0.78
The non-canonical role of vascular endothelial growth factor-C axis in cancer progression. Exp Biol Med (Maywood) (2015) 0.77
Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol (2016) 0.76
Identification of high-affinity VEGFR3-binding peptides through a phage-displayed random peptide library. J Gynecol Oncol (2015) 0.75
STROBE-compliant integrin through focal adhesion involve in cancer stem cell and multidrug resistance of ovarian cancer. Medicine (Baltimore) (2017) 0.75
Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells. Sci Rep (2017) 0.75
Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells. Sci Rep (2017) 0.75
Human CAFs promote lymphangiogenesis in ovarian cancer via the Hh-VEGF-C signaling axis. Oncotarget (2017) 0.75
Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med (2011) 8.93
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med (1996) 7.09
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 5.81
Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol (2002) 4.66
Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun (2013) 4.35
Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev (2006) 4.02
Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med (2004) 3.55
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet (1998) 3.28
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A (2012) 3.21
Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res (2011) 2.50
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene (2008) 2.47
Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res (2006) 2.40
E2Fs up-regulate expression of genes involved in DNA replication, DNA repair and mitosis. Oncogene (2002) 2.39
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol (2011) 2.33
Concise handbook of familial cancer susceptibility syndromes - second edition. J Natl Cancer Inst Monogr (2008) 2.29
Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res (2012) 2.24
Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med (2012) 2.21
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res (2009) 2.04
Vascular leukocytes contribute to tumor vascularization. Blood (2004) 2.03
Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene (2010) 1.73
Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res (2008) 1.53
Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. J Exp Clin Cancer Res (2006) 1.36
Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int J Cancer (1999) 1.35
Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer (2004) 1.33
Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem Cells (2013) 1.33
Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Res (2008) 1.30
Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms. Oncogene (2011) 1.26
VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery (2006) 1.24
Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol (2012) 1.22
Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer (2003) 1.18
Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med (2009) 1.10
Myeloid cell trafficking and tumor angiogenesis. Cancer Lett (2006) 1.10
VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis. Cancer Res (2013) 1.07
Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by Glioma stem-like cells. PLoS One (2013) 1.05
Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells. Cancer Biol Ther (2012) 1.04
Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. Mol Cancer (2011) 1.00
Gonadotropin-regulated lymphangiogenesis in ovarian cancer is mediated by LEDGF-induced expression of VEGF-C. Cancer Res (2009) 1.00
Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol Ther (2008) 0.98
Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A. Neoplasia (2013) 0.96
Inflammation joins the "niche". Cancer Cell (2008) 0.94
Myeloid cells functioning in tumor vascularization as a novel therapeutic target. Transl Res (2007) 0.93
Expression of nestin in lymph node metastasis and lymphangiogenesis in non-small cell lung cancer patients. Hum Pathol (2010) 0.92
Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fixed paraffin-embedded tissue. Virchows Arch (2009) 0.92
Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells. Gynecol Oncol (2001) 0.91
Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opin Investig Drugs (2012) 0.90
Regulation of cancer stem cell activities by tumor-associated macrophages. Am J Cancer Res (2012) 0.90
Multiple VEGF family members are simultaneously expressed in ovarian cancer: a proposed model for bevacizumab resistance. Curr Pharm Des (2012) 0.85
Clinical trials and future potential of targeted therapy for ovarian cancer. Int J Clin Oncol (2012) 0.83
SAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities. Mol Cancer Ther (2012) 0.82
Association between VEGF expression in tumour-associated macrophages and elevated serum VEGF levels in primary colorectal cancer patients. Cancer Biomark (2007) 0.82
A novel model for evaluating therapies targeting human tumor vasculature and human cancer stem-like cells. Cancer Res (2013) 0.78
The newest member of the VEGF family. Blood (2013) 0.76
Inhibition of angiogenesis by a novel neutralizing antibody targeting human VEGFR-3. MAbs (2013) 0.76